The global gastroparesis drugs market size was estimated to be USD 4.68 billion in 2023 and is expected to reach USD 7.76 billion by 2034 with a CAGR of 4.71% during the forecast period 2024-2034. Government initiatives and funding, growing collaborations and partnerships, rising awareness and diagnosis rates, technological advancements in drug development, increasing prevalence of gastroparesis, and advancements in diagnostic technologies will all contribute to the market's growth.
One major factor has been the increasing prevalence of gastroparesis, a disorder marked by delayed stomach emptying. The rising incidence of gastroparesis is a result of factors like diabetes, surgical complications, and neurological illnesses, which raises the need for efficient treatments. More effective and precisely tailored medications to treat gastroparesis have been found and developed thanks to advancements in pharmaceutical research and development. The market has expanded because of the improvement in treatment outcomes brought about by novel drug delivery methods and formulations. For instance, Qinlock (domperidone) was approved by the FDA in April 2023 by Evoke Pharma, Inc. to treat adult patients who have both acute and delayed stomach emptying after surgery.
By drug class, the prokinetic agent's segment accounted for the highest revenue-grossing segment in the global gastroparesis drugs market in 2023 owing to the efficacy of these medications in enhancing gastrointestinal motility, addressing delayed stomach emptying, and providing symptomatic relief to patients, thereby driving their widespread adoption among healthcare practitioners and patients alike. For instance, at the American College of Gastroenterology meeting in August 2022, Neurogastrx, Inc. presented promising clinical trial findings for their investigational medication, NGX 4010, for the treatment of gastroparesis. Additionally, the antiemetic agent segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of the role of antiemetics in managing nausea and vomiting symptoms associated with gastroparesis, coupled with advancements in formulation technologies that enhance the efficacy and tolerability of antiemetic medications.
By disease type, the diabetic gastroparesis segment accounted for the highest revenue-grossing segment in the global gastroparesis drugs market in 2023 owing to the escalating prevalence of diabetes worldwide, particularly type 1 and type 2 diabetes, which significantly contributes to the increased incidence of diabetic gastroparesis. For instance, LGI Pharma reported encouraging Phase 2a study findings in September 2023 for their medication LAN-101, indicating that it may help people with gastroparesis experience less nausea and vomiting. Additionally, the idiopathic gastroparesis segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of gastroparesis cases with no clear underlying cause, the expansion of diagnostic capabilities leading to more accurate identification of idiopathic cases, and a growing emphasis on developing targeted pharmaceutical solutions to address the specific challenges associated with idiopathic gastroparesis.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global gastroparesis drugs market in 2023 owing to the critical role hospitals play as primary healthcare centers, where a substantial number of gastroparesis diagnoses are made and patients receive comprehensive medical care. For instance, AstraZeneca Plc announced in March 2023 that it would be working with Evoke Pharma to co-commercialize Qinlock in the US, thereby increasing its market share in the gastroparesis sector. Additionally, the pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend of outpatient care, rising patient preference for convenient access to medications, and the expanding role of community pharmacies in managing chronic conditions such as gastroparesis.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high prevalence of gastroparesis cases, particularly associated with diabetes, and increasing adoption of advanced pharmaceutical treatments for gastrointestinal disorders. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of gastrointestinal disorders, rising awareness about gastroparesis, and improving healthcare infrastructure. For instance, in February 2022, Vanda Pharmaceuticals Inc. (Vanda) disclosed the results of the Phase III clinical trial, VP-VLY-686-3303, which demonstrated the safety and efficacy of tromapent in treating symptoms of gastroparesis.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
One major factor has been the increasing prevalence of gastroparesis, a disorder marked by delayed stomach emptying. The rising incidence of gastroparesis is a result of factors like diabetes, surgical complications, and neurological illnesses, which raises the need for efficient treatments. More effective and precisely tailored medications to treat gastroparesis have been found and developed thanks to advancements in pharmaceutical research and development. The market has expanded because of the improvement in treatment outcomes brought about by novel drug delivery methods and formulations. For instance, Qinlock (domperidone) was approved by the FDA in April 2023 by Evoke Pharma, Inc. to treat adult patients who have both acute and delayed stomach emptying after surgery.
By drug class, the prokinetic agent's segment accounted for the highest revenue-grossing segment in the global gastroparesis drugs market in 2023 owing to the efficacy of these medications in enhancing gastrointestinal motility, addressing delayed stomach emptying, and providing symptomatic relief to patients, thereby driving their widespread adoption among healthcare practitioners and patients alike. For instance, at the American College of Gastroenterology meeting in August 2022, Neurogastrx, Inc. presented promising clinical trial findings for their investigational medication, NGX 4010, for the treatment of gastroparesis. Additionally, the antiemetic agent segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of the role of antiemetics in managing nausea and vomiting symptoms associated with gastroparesis, coupled with advancements in formulation technologies that enhance the efficacy and tolerability of antiemetic medications.
By disease type, the diabetic gastroparesis segment accounted for the highest revenue-grossing segment in the global gastroparesis drugs market in 2023 owing to the escalating prevalence of diabetes worldwide, particularly type 1 and type 2 diabetes, which significantly contributes to the increased incidence of diabetic gastroparesis. For instance, LGI Pharma reported encouraging Phase 2a study findings in September 2023 for their medication LAN-101, indicating that it may help people with gastroparesis experience less nausea and vomiting. Additionally, the idiopathic gastroparesis segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of gastroparesis cases with no clear underlying cause, the expansion of diagnostic capabilities leading to more accurate identification of idiopathic cases, and a growing emphasis on developing targeted pharmaceutical solutions to address the specific challenges associated with idiopathic gastroparesis.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global gastroparesis drugs market in 2023 owing to the critical role hospitals play as primary healthcare centers, where a substantial number of gastroparesis diagnoses are made and patients receive comprehensive medical care. For instance, AstraZeneca Plc announced in March 2023 that it would be working with Evoke Pharma to co-commercialize Qinlock in the US, thereby increasing its market share in the gastroparesis sector. Additionally, the pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend of outpatient care, rising patient preference for convenient access to medications, and the expanding role of community pharmacies in managing chronic conditions such as gastroparesis.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high prevalence of gastroparesis cases, particularly associated with diabetes, and increasing adoption of advanced pharmaceutical treatments for gastrointestinal disorders. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of gastrointestinal disorders, rising awareness about gastroparesis, and improving healthcare infrastructure. For instance, in February 2022, Vanda Pharmaceuticals Inc. (Vanda) disclosed the results of the Phase III clinical trial, VP-VLY-686-3303, which demonstrated the safety and efficacy of tromapent in treating symptoms of gastroparesis.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Drug Type, Disease Type, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Gastroparesis Drugs Market Report 2023 - 2034
Gastroparesis Drugs Market Analysis & Forecast by Drug Type 2023 - 2034 (Revenue USD Bn)
- Antiemetic Agents
- Prokinetic Agents
- Botulinum Toxin Injections
Gastroparesis Drugs Market Analysis & Forecast by Disease Type 2023 - 2034 (Revenue USD Bn)
- Diabetic Gastroparesis
- Post-Surgical Gastroparesis
- Idiopathic Gastroparesis
- Other Disease Types
Gastroparesis Drugs Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Clinics
- Pharmacies
Gastroparesis Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Gastroparesis Drugs Market: Drug Type Estimates & Trend Analysis
8. Gastroparesis Drugs Market: Disease Type Estimates & Trend Analysis
9. Gastroparesis Drugs Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Gastroparesis Drugs Market
12. Europe Gastroparesis Drugs Market
13. Asia Pacific Gastroparesis Drugs Market
14. Latin America Gastroparesis Drugs Market
15. MEA Gastroparesis Drugs Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Cardinal Health Inc.
- Eisai Co. Ltd.
- Salix Pharmaceuticals
- Neurogastrx Inc.
- Alfa Wassermann S.p.A.
- TE Connectivity Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 4.68 Billion |
| Forecasted Market Value ( USD | $ 7.76 Billion |
| Compound Annual Growth Rate | 4.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
